Literature DB >> 30854492

Ischemic postconditioning decreases iNOS gene expression but ischemic preconditioning ameliorates histological injury in a swine model of extended liver resection.

Elissaios Kontis1,2, Eirini Pantiora2, Aikaterini Melemeni3, Athanasia Tsaroucha3, Eleni Karvouni4, Andreas Polydorou2, Antonios Vezakis2, Georgios P Fragulidis2.   

Abstract

BACKGROUND: Both pre- and postconditioning have been shown to protect the liver parenchyma from ischemia/reperfusion (I/R) injury during hepatectomy by altering the production of NO. However, to date there is no study to compare their effect on the inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS) gene expression, who are the main modulators in the pathway of NO during the acute phase of I/R injury.
METHODS: We designed a prospective experimental cohort comprising of three groups (sham group-SG, preconditioning-PrG and postconditioning group-PoG) and consisting of 10 animals per group. All animals underwent extended hepatectomy (70%) under prolonged warm ischemia either after preconditioning or followed by postconditioning or without any protective maneuver (SG). Following reperfusion blood samples and liver biopsies were obtained at the start of reperfusion (0 hours), at 6 and 12 hours post reperfusion. iNOS and eNOS gene expression was assessed on liver tissue by polymerase chain reaction (PCR); in addition, the extent of hepatocellular injury was histologically assessed.
RESULTS: At the beginning of reperfusion iNOS expression was significantly reduced in the PoG in comparison to the SG (Kruskal-Wallis test, P=0.012; Mann-Whitney U test, P<0.0005 Bonferroni correction) and continued to remain at low levels until 6 hours post reperfusion (Kruskal-Wallis test, P=0.01; Mann-Whitney U test, P<0.0005-Bonferroni correction) This difference was eliminated by 12 hours. No significant differences were found in the expression of eNOS between groups and within time measurements. Aspartate aminotransferase (AST) and Alkaline phosphatase (ALP) were found increased at the start of reperfusion; their levels continued to increase by 6 hours in all groups, however only in the PoG the increase attended statistical significance at 12 hours after reperfusion. ALT levels presented only minor alterations during the course of reperfusion. The PrG was found to have more intense hepatocellular injury at the start of reperfusion than the PoG however, that appeared to gradually settle by 12 hours in contrast to PoG where the hepatocellular injury continued to deteriorate.
CONCLUSIONS: PoG appeared to decrease iNOS overexpression more effectively than PrG in comparison to animals who have undergone no protective maneuver (SG). However, PrG was more effective than PoG in ameliorating the hepatocellular injury observed at 12 hours after the ischemic insult.

Entities:  

Keywords:  Endothelial nitric oxide synthase (eNOS); inducible nitric oxide synthase (iNOS); ischemia/reperfusion injury (I/R injury); liver; resection

Year:  2019        PMID: 30854492      PMCID: PMC6378242          DOI: 10.21037/tgh.2019.01.04

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN: 2415-1289


  38 in total

1.  Minimal protection of the liver by ischemic preconditioning in pigs.

Authors:  R Schulz; M K Walz; M Behrends; T Neumann; G Gerken; G Heusch
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-01       Impact factor: 4.733

2.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

3.  V. Notes on the Arrest of Hepatic Hemorrhage Due to Trauma.

Authors:  J H Pringle
Journal:  Ann Surg       Date:  1908-10       Impact factor: 12.969

Review 4.  Regulation of nitric oxide production by arginine metabolic enzymes.

Authors:  M Mori; T Gotoh
Journal:  Biochem Biophys Res Commun       Date:  2000-09-07       Impact factor: 3.575

5.  Translational control of inducible nitric oxide synthase by IL-13 and arginine availability in inflammatory macrophages.

Authors:  Stefan El-Gayar; Heike Thüring-Nahler; Josef Pfeilschifter; Martin Röllinghoff; Christian Bogdan
Journal:  J Immunol       Date:  2003-11-01       Impact factor: 5.422

6.  Protective effect of ischemic preconditioning against liver injury after major hepatectomy using the intermittent pringle maneuver in swine.

Authors:  Mitsugi Shimoda; Yoshimi Iwasaki; Tokihiko Sawada; Keiichi Kubota
Journal:  Pathobiology       Date:  2007       Impact factor: 4.342

Review 7.  Hepatic ischemia reperfusion injury: pathogenic mechanisms and basis for hepatoprotection.

Authors:  Narci C Teoh; Geoffrey C Farrell
Journal:  J Gastroenterol Hepatol       Date:  2003-08       Impact factor: 4.029

8.  Donor graft adenoviral iNOS gene transfer ameliorates rat liver transplant preservation injury and improves survival.

Authors:  Takashi Kaizu; Atsushi Ikeda; Atsunori Nakao; Yoshihito Takahashi; Allan Tsung; Junichi Kohmoto; Hideyoshi Toyokawa; Lifang Shao; Brian T Bucher; Koji Tomiyama; Michael A Nalesnik; Noriko Murase; David A Geller
Journal:  Hepatology       Date:  2006-03       Impact factor: 17.425

9.  Distribution of NOS isoforms in a porcine endotoxin shock model.

Authors:  Marie-Francoise Doursout; Takeshi Oguchi; Uwe M Fischer; YangYan Liang; Brice Chelly; Craig J Hartley; Jacques E Chelly
Journal:  Shock       Date:  2008-06       Impact factor: 3.454

Review 10.  Grading and staging systems for inflammation and fibrosis in chronic liver diseases.

Authors:  Zachary D Goodman
Journal:  J Hepatol       Date:  2007-07-30       Impact factor: 25.083

View more
  1 in total

1.  Protective Effects of Ischemic Postconditioning on Livers in Rats with Limb Ischemia-Reperfusion via Glycogen Synthase Kinase 3 beta (GSK-3β)/Fyn/Nuclear Receptor-Erythroid-2-Related Factor (Nrf2) Pathway.

Authors:  Qibing Niu; Wanli Sun; Quan Chen; Yang Long; Wanjun Cao; Shiqi Wen; Anqiang Li; Fang Dong; Hao Shi
Journal:  Med Sci Monit       Date:  2020-07-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.